| Register & Login: |  |
The following articles have the tag varenicline
THE difference between well-trained and untrained physicians managing patient smoking cessation can be greater than the difference between taking medication or placebo, according to a UK expert.
A NEW analysis demonstrating the effectiveness of varenicline in helping people to quit smoking should not sway doctors from first attempting non-pharmacological methods with their patients, a leading public health expert has urged.
CONCERNS that the smoking cessation drug varenicline is associated with an increased risk of suicidal ideation and depression may be allayed by new research from UK health regulators. Researchers reviewed data from the UK general practice database including 80,000 adults prescribed a new course of a smoking cessation product from September 2006 to May 2008. Almost 11,000 of these patients were prescribed varenicline. Compared with users of nicotine replacement therapies, there was a non-significant 12% increased risk of self-harm among varenicline users. There was no evidence of an association with an increased risk of depression or suicidal ...
AUSTRALIAN regulators are reviewing the safety of widely used smoking cessation products varenicline (Champix) and bupropion (Zyban and generic alternatives) after a number of reports of serious neuropsychiatric symptoms following their use. The US Food and Drug Administration (FDA) recently announced that following analysis of post-marketing adverse events, it would require manufacturers to add black box warnings regarding the risk of suicidal ideation and behaviour in patients with no history of psychiatric illness. The manufacturers are also expected to update prescribing information and patient medication guidelines with similar warnings. To the end of March 2009, the ...
REPORTS of adverse reactions to the anti-smoking drug varenicline (Champix) have increased markedly since it was listed on the PBS at the beginning of the year. The Adverse Drug Reactions Bulletin warned it was “increasingly likely with accumulating evidence that there is an association between varenicline and serious neuropsychiatric events”. To October 2008, there had been 339 reports of adverse reactions to the drug, 255 of which related to psychiatric symptoms. A more detailed breakdown provided by the TGA found there had been 44 reports involving depression, 39 of suicidal ideation, 22 cases of aggression and 19 ...